- Home
- TURN vs OKUR Comparison
TURN vs OKUR Comparison
Compare TURN & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- OKUR
- Stock Information
- Founded
- TURN 1981
- OKUR 2011
- Country
- TURN United States
- OKUR United States
- Employees
- TURN N/A
- OKUR N/A
- Industry
- TURN Finance/Investors Services
- OKUR
- Sector
- TURN Finance
- OKUR
- Exchange
- TURN Nasdaq
- OKUR NYSE
- Market Cap
- TURN 39.9M
- OKUR 34.9M
- IPO Year
- TURN N/A
- OKUR N/A
- Fundamental
- Price
- TURN $4.06
- OKUR $1.84
- Analyst Decision
- TURN
- OKUR Strong Buy
- Analyst Count
- TURN 0
- OKUR 4
- Target Price
- TURN N/A
- OKUR $32.25
- AVG Volume (30 Days)
- TURN 31.5K
- OKUR 118.0K
- Earning Date
- TURN 05-27-2025
- OKUR 05-06-2025
- Dividend Yield
- TURN N/A
- OKUR N/A
- EPS Growth
- TURN N/A
- OKUR N/A
- EPS
- TURN N/A
- OKUR N/A
- Revenue
- TURN $194,813.00
- OKUR N/A
- Revenue This Year
- TURN N/A
- OKUR N/A
- Revenue Next Year
- TURN N/A
- OKUR N/A
- P/E Ratio
- TURN N/A
- OKUR N/A
- Revenue Growth
- TURN 254.25
- OKUR N/A
- 52 Week Low
- TURN $3.12
- OKUR $1.98
- 52 Week High
- TURN $4.23
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- TURN 60.66
- OKUR N/A
- Support Level
- TURN $3.68
- OKUR N/A
- Resistance Level
- TURN $4.19
- OKUR N/A
- Average True Range (ATR)
- TURN 0.30
- OKUR 0.00
- MACD
- TURN 0.02
- OKUR 0.00
- Stochastic Oscillator
- TURN 72.58
- OKUR 0.00
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.